

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare announces result for the first half of the 2022 financial year

Auckland, New Zealand, 25 November 2021 – Fisher & Paykel Healthcare Corporation Limited today announced its results for the first half of the 2022 financial year.

For the six months ended 30 September 2021, total operating revenue was \$900 million. This was a 1% decline from the same period in the previous financial year, or a 2% increase in constant currency. Net profit after tax for the first half was \$222 million, a 2% decline from the prior comparable period, or a 1% decline in constant currency.

Managing Director and CEO Lewis Gradon said, “For nearly two years now, our customers have been working selflessly to care for patients during a pandemic. Our people and our suppliers have also been working under demanding circumstances, and we are grateful for their relentless commitment.

“As you may recall, the first half of the last financial year was a period of extraordinary demand during the initial surges of COVID-19. Our financial results in the first half of the 2022 financial year have continued to be very strong,” Mr Gradon continued.

In the Hospital product group, which includes humidification products used in respiratory, acute and surgical care, revenue for the first half was \$670 million, a decline of 2% from the first half of the 2021 financial year, or an increase of 1% in constant currency. Hospital consumables grew 8% in constant currency, and of total Hospital product group revenue, 67% was from the sale of consumables and 33% was from the sale of hardware.

In the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, revenue was \$227 million, a 0.3% increase over the prior comparable period, or 3% in constant currency.

Gross margin was 63.1%, up 135 basis points or 53 basis points in constant currency compared to the first half of the 2021 financial year. Elevated freight costs and air freight utilisation continued but were lower than the same period last year, impacting gross margin by approximately 190 basis points compared to pre-COVID-19 levels.

The company’s directors have approved an interim dividend of 17 cents per ordinary share. The interim dividend, carrying full New Zealand imputation credit, will be paid on 15 December 2021 with a record date of 3 December 2021.

The company also announced that over the next five years it expects to invest approximately \$700 million in land and buildings. This includes a fifth building completing its Auckland campus and acquiring land for a second New Zealand campus. Over the next five years the company expects to add an additional three manufacturing facilities located outside New Zealand, the first of which is currently under construction in Tijuana, Mexico.

“The longer-term impact from COVID-19 for our business has been a larger installed base of our hospital hardware and increased global physician awareness and experience with our therapies and products. To ensure we are well-positioned to meet demand for the ongoing use of this installed base of hardware and accommodate our strong new product pipeline, we are continuing to invest in our infrastructure to ensure it supports our long-term growth,” said Mr Gradon.

Given the continuing uncertainties associated with COVID-19, including the impact on hospitalisations and public and civic responses to COVID-19 case numbers, the company is not providing quantitative revenue or earnings guidance for the remainder of the 2022 financial year.

“We have not changed our view on outlook for the remainder of the financial year since we last provided an update on the 18th of August,” said Mr Gradon.

“For the second half, we expect our Hospital hardware sales will continue to be impacted by COVID-19-related hospital admissions. However, as we said in our August trading update, many countries have already boosted their hospital treatment capacity, so we do not expect Hospital hardware revenue to continue at an elevated level for the rest of the year.

“In our Hospital product group, consumables volume is likely to be impacted by a number of different factors. Those include the ongoing COVID-19 hospitalisations around the world, the severity of the flu season during the Northern Hemisphere winter, and the ability of hospitals to return to their pre-COVID-19 rates for surgeries.

“Our second half last year corresponded to peak COVID-19 hospitalisations in North America and most European countries. In the absence of further comparable hospitalisation surges around the world, we would expect our consumables revenue for the second half of this financial year to be lower than the second half last year. Continuing endemic COVID-19 hospitalisations, surgical activity approaching normality and the ongoing adoption of nasal high flow for applications other than COVID-19 would result in our consumables revenue increasing sequentially from the first half of this year.

“In our Homecare product group, growth in OSA masks is dependent on new patient diagnosis rates, which may continue to be impacted by COVID-19 and the supply of treatment hardware. We continue to expect new patient diagnoses to be at or above FY21 rates for the second half of the 2022 financial year.

“Ongoing localised surges in COVID-19 cases and civic responses indicate that it may yet be a long journey to get to a point where business and life are more predictable. Whatever the future holds, we are unified in our belief that doing what is best for patients will deliver the best outcomes for the business,” concluded Mr Gradon.

Overview of key results for the first half of the 2022 financial year

- 2% decline in net profit after tax to \$221.8 million.
- 1% decline in operating revenue to \$900.0 million, or 2% growth in constant currency.
- 2% decline in Hospital operating revenue to \$670.2 million, or 1% growth in constant currency.
- 24% constant currency revenue growth for new applications consumables; i.e. products used in noninvasive ventilation, Optiflow nasal high flow therapy and surgical applications, accounting for 72% of Hospital consumables revenue.
- 0.3% growth in Homecare operating revenue, or 3% growth in constant currency.
- Investment in R&D was 8% of revenue, or \$75.7 million.
- 6% increase in interim dividend to 17 cps (H1 FY21: 16 cps).

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Ends

Media & Investor Contacts:

Karen Knott
General Manager - Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911

Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 27 807 8073

Authorised by Fisher & Paykel Healthcare Corporation Limited's Board of Directors.

Accompanying Documents

Attached to this news release are the following additional documents:

- Results in Brief
- Interim Report 2022
- Investor Presentation
- NZX Results Announcement
- NZX Distribution Notice

Constant Currency Information

Constant currency information included within this news release is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A constant currency analysis is included on page 13 of the company's Interim Report 2022, and the company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half Year Results Conference Call

Fisher & Paykel Healthcare will host a conference call today to discuss the results for the first half of the 2022 financial year. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT Thursday, 25 November (4:00pm UEST, Wednesday 24 November) and will be webcast.

To listen to the webcast, access the company's website at www.fphcare.com/investor. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.

To attend the conference call, participants should dial in to one of the numbers below at least five minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: **245311**.

New Zealand	+64 9 913 3624	US/Canada	+1 323 794 2095
Australia	+61 2 7250 5438	Hong Kong	+852 3008 1533
United Kingdom	+44 330 336 9104	International	+64 9 913 3624

Results in Brief

	Six Months Ended 30 Sep 20 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 21 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency ¹)
FINANCIAL PERFORMANCE				
Total operating revenue	910.2	900.0	-1%	+2%
Cost of sales	(348.3)	(332.3)	-5%	+0.5%
Gross profit	561.9	567.7	+1%	+3%
Gross margin	61.7%	63.1%	+135bps	+53bps
Selling, general and administrative expenses	(188.1)	(189.6)	+1%	+5%
Research and development expenses	(64.6)	(75.7)	+17%	+17%
R&D percentage of operating revenue	7.1%	8.4%	+131bps	+114bps
Total operating expenses	(252.7)	(265.3)	+5%	+8%
Operating profit before financing costs	309.2	302.4	-2%	-2%
Operating margin	34.0%	33.6%	-37bps	-121bps
Net financing income (expense)	3.8	(1.3)	-135%	-15%
Profit before tax	313.0	301.1	-4%	-2%
Tax expense	(87.5)	(79.3)	-9%	-4%
Profit after tax	225.5	221.8	-2%	-1%
Effective tax rate	28.0%	26.3%		
Effective tax rate excluding R&D tax credit	30.0%	28.8%		

Revenue by Region:

North America	373.9	329.8	-12%
Europe	269.9	232.0	-14%
Asia Pacific	184.4	267.2	+45%
Other	82.0	71.0	-13%
Total	910.2	900.0	-1%

Revenue by Product Group:

Hospital	681.0	670.2	-2%
Homecare	226.2	226.9	+0.3%
Core products sub-total	907.2	897.1	-1%
Distributed and other	3.0	2.9	-2%
Total	910.2	900.0	-1%

	As at 31 Mar 21 NZ\$M (except as otherwise stated)	As at 30 Sep 21 NZ\$M (except as otherwise stated)	
FINANCIAL POSITION			
Tangible assets	1,913.7	1,856.9	-3%
Intangible assets ²	161.3	188.5	+17%
Total assets	2,075.0	2,045.4	-1%
Total liabilities	(554.1)	(454.6)	-18%
Shareholders' equity	1,520.9	1,590.8	+5%
Gearing	(27.2%)	(16.6%)	10.6%
Net tangible asset backing (cents per share)	236	243	+3%

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf. The reconciliation to reported results is included within the Financial Commentary section of the Interim Report.

² Includes Intangible and deferred tax assets.

Results in Brief (continued)

	Six Months Ended 30 Sep 20 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 21 NZ\$M (except as otherwise stated)	% Change
CASH FLOWS			
Net cash flow from operating activities	218.1	127.5	-42%
Net cash flow (used in) investing activities	(81.9)	13.8	-117%
Net cash flow (used in) financing activities	(92.9)	(131.9)	+42%
SHARES OUTSTANDING			
Weighted average basic shares outstanding	574,981,039	576,615,929	
Weighted average diluted shares outstanding	579,449,729	579,772,363	
Basic shares outstanding at period end	576,123,608	577,131,310	
DIVIDENDS AND EARNINGS PER SHARE			
Dividends per share (cents) – declared	16.0	17.0	+6%
Basic earnings per share (cents)	39.2	38.5	-2%



Forward, together.

Contents

HALF YEAR FINANCIAL HIGHLIGHTS	2
HALF YEAR BUSINESS UPDATES	3
PRODUCT GROUP OVERVIEW	4
HALF YEAR REVIEW	6
FINANCIAL COMMENTARY	10
FINANCIAL STATEMENTS	14
NOTES TO THE FINANCIAL STATEMENTS	18
DIRECTORY	24

Constant currency information contained within this report is non-conforming financial information, as defined by the NZ FMA and has been provided to assist users of financial information to better understand and assess the company's financial performance without the impacts of spot financial currency fluctuations and hedging results, and has been prepared on a consistent basis each financial year. A reconciliation between reported results and constant currency results is available on page 13 of this report. The company's constant currency framework can be found on our website at www.fphcare.com/ccf.

This report is dated 24 November 2021 and is signed on behalf of Fisher & Paykel Healthcare Corporation Limited by Scott St John, Board Chair and Lewis Gradon, Managing Director and Chief Executive Officer.



SCOTT ST JOHN, BOARD CHAIR



LEWIS GRADON, MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

For nearly two years now, our customers have been working selflessly to care for patients during a pandemic, and our people have been committed to delivering for those customers.

It may yet be a long journey to get to a point where business and life are more predictable. Whatever the future holds, we are focussed on moving forward, together.



HALF YEAR financial highlights

OPERATING REVENUE

\$900.0M

▼ 1% | 1H FY21 \$910.2M

NET PROFIT AFTER TAX

\$221.8M

▼ 2% | 1H FY21 \$225.5M

GROSS MARGIN

63.1%

INTERIM DIVIDEND FULLY IMPUTED

17CPS

▲ 6% | 1H FY21 16CPS

SPEND ON R&D

\$75.7M

8% OF OPERATING REVENUE

HOSPITAL REVENUE

\$670.2M

▼ 2% | 1H FY21 \$681.0M

HOSPITAL NEW APPLICATIONS CONSUMABLES REVENUE GROWTH



↑24%

(CONSTANT CURRENCY)

HALF YEAR business updates



REVENUE BY REGION

6 MONTHS TO 30 SEPTEMBER 2021



REVENUE BY PRODUCT GROUP

6 MONTHS TO 30 SEPTEMBER 2021



CONTRIBUTED to the fight against COVID-19 by providing convenient access to vaccinations for our employees.

LAUNCHED F&P Visairo™ mask for noninvasive ventilation and F&P Evora™ Full mask for obstructive sleep apnea.

APPOINTED Dr Lisa McIntyre to the Board of directors.

COMMENCED construction on our third manufacturing facility in Mexico and started earthworks on our fifth facility in New Zealand.

INITIATED search for property to build a second R&D and manufacturing campus in New Zealand.

CONTINUED to expand our global reach by placing sales representatives into additional countries.

Product group overview

Our business is structured in two parts: Hospital and Homecare.

Our Hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Not only do these products help healthcare providers improve patient outcomes, they often deliver economic benefits as well, by reducing the need to escalate care and shortening patient stays in hospital.

Hospital



74%

OF OPERATING REVENUE

OPERATING REVENUE
1H FY22 ▼ 2%

\$670.2M

CONSTANT CURRENCY REVENUE FROM
NEW APPLICATIONS CONSUMABLES

↑24%

The Homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home. These include our CPAP therapy masks as well as flow generators, interfaces, and data management technologies.

Homecare



F&P Evora Full

25%

OF OPERATING REVENUE

OPERATING REVENUE
1H FY22 ▲ 0.3%

\$226.9M

CONSTANT CURRENCY
REVENUE

↑3%

Half year review

As we write this, the world has surpassed 250 million recorded cases of COVID-19. Some countries appear to have flattened the curve, and others are responding to third and fourth waves.

Healthcare providers have been caring for COVID-19 patients, along with patients with other illnesses, for nearly two years now. A simple 'thank you' cannot begin to express the gratitude they deserve. Working under incredibly demanding circumstances, they have shown remarkable compassion and commitment.

The people of Fisher & Paykel Healthcare and our suppliers have also been working under demanding circumstances – maintaining higher production levels, advancing new projects, and supporting customers while dealing with the daily impacts of COVID-19 in their communities and homes. Thanks to their effort, we have achieved another extraordinary result.

Financial result

The first half of the previous financial year was a period of extraordinary demand during the initial surges of COVID-19. Our results for

the first half of the 2022 financial year have continued to be very strong.

Elevated demand for most of our hospital products has followed the global surges of COVID-19, and this is reflected in our revenue for the first half. For the six months ended 30 September 2021, total operating revenue was \$900.0 million. This was 1 per cent below the same period of the previous financial year, or a 2 per cent increase in constant currency. Net profit after tax was \$221.8 million, a 2 per cent decline from the same period in the previous financial year, or a 1 per cent decline in constant currency.

Once again, our result was largely driven by our Hospital product group, which comprised 74 per cent of revenue. Within the Hospital product group, revenue for the first half was \$670.2 million, a decline of 2 per cent compared to the first half of the 2021 financial year, or an increase of 1 per cent in constant currency.

When we announced our year-end results in May, we expected that Hospital hardware sales would continue to be impacted by COVID-19-related hospital admissions. This proved to be the case in the last two months of the half-year, as North America in particular experienced a COVID-19 hospitalisation surge. Hospital hardware



SCOTT ST JOHN
Board Chair



LEWIS GRADON
Managing Director and
Chief Executive Officer

It may be a long journey to get to the point where business and life are more predictable.

sales declined 10 per cent in constant currency for the half, and we do not expect our Hospital hardware sales to remain at this elevated level for the remainder of the year. Sales of Hospital consumables grew in the first half, up 8 per cent over the prior comparable period in constant currency. Sales of new applications consumables grew 24 per cent in constant currency in the first half, reflecting the change in clinical practice towards nasal high flow therapy.

In our Homecare product group, revenue was \$226.9 million, a 3 per cent increase over the first half of the previous financial year in constant currency. Continuing COVID-19 restrictions, along with a limited supply of continuous positive airway pressure (CPAP) devices worldwide, may have impacted the number of new patients diagnosed with obstructive sleep apnea (OSA). Our Vitera™ and Evora masks are performing well, and we were pleased to see 3 per cent growth in constant currency in OSA masks and accessories compared with the first half of the 2021 financial year.

Strategic progress

While there are still some challenges accessing our customers in hospitals to test and trial our new products, we are continuing to make progress with product

launches. In August, we released the Visairo mask for noninvasive ventilation in the United States, and in October, we launched the Evora Full mask for OSA in New Zealand and Australia. Our commitment to researching and developing new products is unwavering, and our investment in R&D for the first six months of the financial year was \$75.7 million.

In the first half, we also made good progress on new buildings to support our growth. We have always carried additional manufacturing and distribution capacity so that we can scale up quickly in response to a crisis. Maintaining that ability requires space and buildings, and over the next five years, we expect to invest approximately \$700 million for this purpose. This includes constructing a fifth building in Auckland, completing our Auckland campus, and acquiring land for a second New Zealand campus where we can co-locate R&D and manufacturing. Our long-term plan is to add an additional three manufacturing facilities located outside New Zealand, the first of which is currently under construction in Tijuana, Mexico.

Board update

Our search for a Board member to replace Tony Carter was a lengthy one, made more difficult by COVID-19 travel restrictions. In October, we were delighted to appoint Dr Lisa McIntyre to the Board. Lisa has extensive knowledge in health and technology, with experience in strategy, finance, technology transformation and data analytics. She has already provided valuable insights, and we believe we will benefit from her deep understanding of international markets.

Dividend

The Board of Directors has approved an interim dividend of 17 cents per share for the six months to 30 September 2021, which is an increase of 6 per cent from the first half of the 2021 financial year. The dividend will be paid on 15 December 2021 with a record date of 3 December.

Profit share

Our people continue to manage demand surges for our products due to COVID-19, as well as ongoing supply chain challenges obtaining raw materials and delivering finished goods to our customers. All of our facilities around the world continue

to change and evolve their work practices in response to local conditions – to keep our people safe and our product supply stable for the patients who rely on us. We want to recognise everyone for uniting together to mitigate the global impact of the pandemic, as well as the efforts of our global team toward our goal of getting 100 per cent of our people vaccinated. The Board has therefore decided to double the interim discretionary profit-sharing bonus for everyone who has worked with us for a qualifying period. The profit-sharing bonus totals \$12 million.

Moving forward together

Ongoing localised surges in COVID-19 cases and civic responses indicate that it may yet be a long journey to get to a point where business and life are more predictable. Whatever the future holds, we are focussed on moving forward together. Our purpose unites us – improving care and outcomes through inspired and world-leading healthcare solutions – and we are unified in our belief that doing what is best for patients will deliver the best outcomes for the business.

Thank you

On behalf of the Board, we would like to express our appreciation to our customers for their perseverance. We would also like to thank the people of Fisher & Paykel Healthcare for their relentless commitment, and our suppliers for going the extra mile. As always, we thank you, our shareholders, for your ongoing support.



SCOTT ST JOHN
BOARD CHAIR



LEWIS GRADON
MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

Financial report



Financial commentary

INCOME STATEMENTS

For the six months ended 30 September	2020 NZ\$M	2021 NZ\$M	Change Reported %	Change CC ¹ %
Operating revenue	910.2	900.0	-1	+2
Gross profit	561.9	567.7	+1	+3
Gross margin	61.7%	63.1%	135 bps	53 bps
SG&A expenses	(188.1)	(189.6)	+1	+5
R&D expenses	(64.6)	(75.7)	+17	+17
Total operating expenses	(252.7)	(265.3)	+5	+8
Operating profit	309.2	302.4	-2	-2
Operating margin	34.0%	33.6%	-37 bps	-121 bps
Net financing income (expense)	3.8	(1.3)	-	-
Profit before tax	313.0	301.1	-4	-2
Tax expense	(87.5)	(79.3)	-9	-4
Profit after tax	225.5	221.8	-2	-1

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. See further details on page 13.

Total profit after tax for the period was \$221.8 million, a 2% decline from the prior comparable period (1% decline in constant currency).

Revenue

Total operating revenue was \$900.0 million. This was a 1% decline from the same period last year or a 2% increase in constant currency. The first half of last financial year was a period of extraordinary demand during the initial surges of COVID-19. The revenue in this period has continued to be very strong. Hospital revenue grew 1% in constant currency. Homecare revenue grew 3% in constant currency.

Gross margin

Gross margin increased by 53 basis points in constant currency due to a lower level of elevated freight costs and air freight utilisation in this period compared to the prior year. Excluding the additional freight costs, a 65% gross margin was achieved in reported currency.

Operating expenses

Operating expenses increased 5% (8% in constant currency) to \$265.3 million, reflecting ongoing expenditure to support global sales growth and development of our product pipeline.

R&D spend of \$75.7 million grew 17% reflecting underlying growth and the timing of R&D and clinical projects. Over the long term R&D spend is expected to grow in line with constant currency revenue growth.

Financing expenses


The net financing expense increase reflects the gain on foreign exchange revaluations in the prior period not repeating this period. Excluding the impact of foreign currency movements, net financing expense was in line with the prior period.

Tax

The effective tax rate for the period was 26.3%, down from 28.0% in the prior year. The R&D tax credit reported this period of \$7.4 million (Sep 2020: \$6.4 million) represents the estimated eligible R&D expenditure incurred during the period. Excluding the R&D tax credit the effective tax rate was 28.8% (Sep 2020: 30.0%).

FOREIGN CURRENCY IMPACTS

The Group is exposed to movements in foreign exchange rates, with approximately 99% of operating revenue generated in currencies other than NZD as shown below.



Approximately 60% of COGS and over 50% of operating expenses are in currencies other than NZD.

During the period since 31 March 2021, the NZD weakened slightly against major currencies. The effect of balance sheet translations for the period resulted in an increase in operating revenue of \$2.5 million (Sep 2020: \$10.6 million decrease) and an increase in profit after tax of \$2.4 million (Sep 2020: \$3.6 million decrease). The hedging programme contributed a pre-tax gain of \$21.1 million (Sep 2020: \$1.4 million loss).

The average daily spot rate and the average conversion exchange rate (i.e. the accounting rate, incorporating the benefit of forward exchange contracts in respect of the relevant financial year) of the main foreign currency exposures for the reported periods are set out in the table below.

Average daily spot and conversion rates for the period ended 30 September

	Average daily spot rate		Average conversion exchange rate	
	2020	2021	2020	2021
Six months ended 30 September				
USD	0.6403	0.7077	0.6551	0.6769
EUR	0.5639	0.5938	0.5559	0.5594

Net profit after tax was reduced by \$1.6 million compared to the prior period due to the impact of foreign currency. Excluding the impact of favourable balance sheet translations, unfavourable impacts reflect a stronger NZD and higher average exchange rates compared to the prior comparable period, particularly against the USD (See further details on page 13).

Foreign exchange hedging position

In line with our hedging programme, additional hedges have been added for future years, in particular for financial years 2023 to 2024. The hedging position for our main currency exposures as at 11 November 2021 is:

Year to 31 March	2022	2023	2024	2025	2026-27
USD % cover of estimated exposure	95%	70%	50%	30%	-
USD average rate of cover	0.675	0.665	0.656	0.624	-
EUR % cover of estimated exposure	95%	70%	45%	35%	5%
EUR average rate of cover	0.554	0.537	0.526	0.508	0.481

Hedging cover has been rounded to the nearest 5%.

CASH FLOWS

The full statement of cash flows is provided on page 17.

	2020 NZ\$M	2021 NZ\$M	Change NZ\$M
For the six months ended 30 September			
Operating profit before financing costs	309.2	302.4	(6.8)
Plus depreciation and amortisation	37.0	46.0	9.0
Change in working capital and other	(45.5)	(31.2)	14.3
Net interest paid	(1.9)	(1.7)	0.2
Net income tax paid	(80.7)	(188.0)	(107.3)
Operating cash flows	218.1	127.5	(90.6)
Lease repayments	(5.3)	(6.6)	(1.3)
Purchase of land and buildings	(13.5)	(14.7)	(1.2)
Purchase of plant and equipment	(64.9)	(50.1)	14.8
Purchase of intangible assets	(16.1)	(16.5)	(0.4)
Free cash flows	118.3	39.6	(78.7)
Dividends paid	(89.1)	(126.8)	(37.7)

Operating cash flows

Cash flows from operations for the period decreased 42% to \$127.5 million. Excluding the tax payments, operating cash flows increased 6%. Working capital continued to be impacted by increases in inventories relating to building raw materials and finished goods to be able to meet potential surge demand.

Capital expenditure

Property plant and equipment and intangible asset purchases for the period were \$81.3 million, a decrease of \$13.2 million from the prior year. Capital expenditure was elevated in the prior period due to the acceleration of manufacturing equipment projects.

Dividends

Dividends paid of \$126.8 million were 42% higher than the prior period representing the increase in final dividend.

BALANCE SHEET

	31 March 2021 NZ\$M	30 September 2021 NZ\$M	Change NZ\$M
As at			
Trade receivables	191.7	201.7	10.0
Inventories	270.6	291.8	21.2
Less trade and other payables *	(145.8)	(126.4)	19.4
Working capital	316.5	367.1	50.6
Property, plant and equipment **	882.1	917.4	35.3
Intangible assets	80.0	83.4	3.4
Other net assets (liabilities)	(16.9)	49.0	65.9
Lease liabilities	(43.7)	(42.2)	1.5
Net cash	302.9	216.1	(86.8)
Net assets	1,520.9	1,590.8	69.9

* Trade and other payables excludes all non-current payables and all employee entitlements and provisions

** Property, plant and equipment includes lease assets recognised

Trade receivables at 30 September 2021 reflected the continued strong sales and collections. Debtor days were within the normal range at 41 days (March 2021: 43 days). Inventories balances increased with the continued build in raw materials and finished goods to enable the supply of products in the event of any surges in demand. Trade and other payables reduction includes timing associated with key capital projects and due dates for payment of suppliers.

The increase in property, plant and equipment included capital additions (including leased assets) of \$68.9 million, the majority of which related to production tooling and equipment additions. These increases were offset by \$32.4 million of depreciation. During the period, the build of the third manufacturing facility in Mexico commenced, and earthworks began in preparation for a fifth building in New Zealand.

Intangible assets increased by \$3.4 million, including patent acquisition costs. Included in intangible assets is ERP system capital spending with our global SAP rollout continuing over the next two to three years.

Other net assets/liabilities movements included the reduction in tax payables of \$101.6 million offset by a decrease in net derivative financial instrument assets of \$43.1 million. All currency derivatives continued to be effective hedges.

Net cash and debt facilities

As at	31 March 2021 NZ\$M	30 September 2021 NZ\$M	Change NZ\$M
Loans and borrowings			
– Current	–	–	–
– Non-current	(62.8)	(63.5)	(0.7)
Bank overdrafts	(11.9)	(8.8)	3.1
Total interest-bearing liabilities *	(74.7)	(72.3)	2.4
Cash and cash equivalents	97.3	103.2	5.9
Short-term investments	280.3	185.2	(95.1)
Total cash and investments	377.6	288.4	(89.2)
Net cash	302.9	216.1	(86.8)
Gearing	-27.2%	-16.6%	10.6%
Undrawn debt facilities	167.2	185.0	17.8

* Excluding lease liabilities

The average maturity of loans and borrowings of \$63.5 million was 1.4 years and the currency split was 92% USD; 5% Australian dollars; and 3% Canadian dollars (with no NZD denominated debt).

On 30 September 2021, a NZ\$30 million facility expired and was replaced with a US\$40 million revolving facility that commenced on 22 September 2021 and expires on 31 October 2024.

Cash and short-term investments, mainly in NZD, were \$288.4 million at 30 September 2021. This balance, and operating cash generated in the second half of FY2022, will fund the payment of the interim dividend, provisional tax and ongoing capital expenditure including manufacturing capacity expansion and building projects in Mexico and Auckland.

Gearing¹

At 30 September 2021 the group had gearing of -16.6%. Gearing was outside the target range of -5% to +5%.

NOTES – CONSTANT CURRENCY

Constant currency analysis is non-Generally Accepted Accounting Practice (GAAP) financial information, that is not prepared in accordance with New Zealand Equivalents to International Financial Reporting Standards (NZ IFRS). Constant currency information has been provided to assist users of financial information to better understand and assess the Group's financial performance without the impacts of foreign currency fluctuations, including hedging results.

Constant currency financial information is prepared each month to enable the Board and management to monitor and assess the Group's underlying comparative financial performance without any distortion from changes in foreign exchange rates. Constant currency information is prepared on a consistent basis for reported periods restated into NZD based on "constant" exchange rates, typically the budgeted exchange rates for the current year. This information excludes the impact of movements in foreign exchange rates, hedging results and balance sheet translations.

The Group's constant currency framework can be found on the company's website at www.fphcare.com/ccf. PwC perform assurance procedures over the constant currency information.

RECONCILIATION OF CONSTANT CURRENCY TO REPORTED PROFIT AFTER TAX

For the six months ended 30 September	2020 NZ\$M	2021 NZ\$M	Change NZ\$M
Profit after tax (constant currency)	200.9	198.8	(2.1)
Spot exchange rate effect	29.2	5.4	(23.8)
Foreign exchange hedging result	(1.0)	15.2	16.2
Balance sheet revaluation	(3.6)	2.4	6.0
Profit after tax (reported)	225.5	221.8	(3.7)

The significant exchange rates used in the constant currency analysis, being the budget exchange rates for the year ended 31 March 2022, are USD 0.72, EUR 0.60, AUD 0.93, GBP 0.52, CAD 0.92, JPY 78, MXN 15.2, CNY 4.7, KRW 820, SEK 6.1 and INR 53.

¹ Net interest-bearing debt (debt less cash and cash equivalents and short-term investments) to net interest-bearing debt and equity (less hedging reserves). Net interest-bearing debt excludes lease liabilities.

Financial statements

CONSOLIDATED INCOME STATEMENT

For the six months ended 30 September 2021

	Notes	Unaudited 2020 NZ\$M	Unaudited 2021 NZ\$M
Operating revenue	3	910.2	900.0
Cost of sales		(348.3)	(332.3)
Gross profit		561.9	567.7
Selling, general and administrative expenses		(188.1)	(189.6)
Research and development expenses		(64.6)	(75.7)
Total operating expenses		(252.7)	(265.3)
Operating profit before financing costs		309.2	302.4
Financing income		0.9	1.2
Financing expense		(2.4)	(2.4)
Exchange gain/(loss) on foreign currency interest-bearing liabilities		5.3	(0.1)
Net financing income (expense)		3.8	(1.3)
Profit before tax	4	313.0	301.1
Tax expense		(87.5)	(79.3)
Profit after tax		225.5	221.8
Basic earnings per share		39.2 cps	38.5 cps
Diluted earnings per share		38.9 cps	38.3 cps

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 September 2021

	Unaudited 2020 NZ\$M	Unaudited 2021 NZ\$M
Profit after tax	225.5	221.8
Other comprehensive income		
<i>Items that may be reclassified to profit or loss</i>		
Foreign currency translation reserve		
Exchange differences on translation of foreign operations	(4.4)	1.2
Hedging reserves		
Changes in fair value in hedging reserves	143.8	(22.2)
Transfers to profit before tax from cash flow hedge reserve	2.3	(21.0)
Tax on above reserve movements	(40.9)	12.1
Other comprehensive income, net of tax	100.8	(29.9)
Total comprehensive income	326.3	191.9

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 September 2021

	Notes	Share capital NZ\$M	Retained earnings NZ\$M	Reserves NZ\$M	Total equity NZ\$M
Balance at 31 March 2020 (audited)		225.4	686.3	62.1	973.8
Total comprehensive income		–	225.5	100.8	326.3
Dividends paid	9	–	(89.1)	–	(89.1)
Issue of share capital under employee share plans		18.1	–	–	18.1
Movement in treasury shares		1.3	–	–	1.3
Movement in share based payments reserve		–	–	(7.3)	(7.3)
Balance at 30 September 2020 (unaudited)		244.8	822.7	155.6	1,223.1
Balance at 31 March 2021 (audited)		249.1	1,029.2	242.6	1,520.9
Total comprehensive income		–	221.8	(29.9)	191.9
Dividends paid	9	–	(126.8)	–	(126.8)
Issue of share capital under employee share plans		6.4	–	–	6.4
Movement in share based payments reserve		–	–	(1.6)	(1.6)
Balance at 30 September 2021 (unaudited)		255.5	1,124.2	211.1	1,590.8

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED BALANCE SHEET

As at 30 September 2021

	Notes	Audited 31 March 2021 NZ\$M	Unaudited 30 September 2021 NZ\$M
ASSETS			
Current assets			
Cash and cash equivalents		97.3	103.2
Short-term investments		280.3	185.2
Trade and other receivables		222.5	236.6
Inventories		270.6	291.8
Derivative financial instruments	5	42.9	38.9
Tax receivable		6.4	12.0
Total current assets		920.0	867.7
Non-current assets			
Derivative financial instruments	5	104.0	70.0
Other receivables		7.6	1.8
Property, plant and equipment		882.1	917.3
Intangible assets		80.0	83.5
Deferred tax assets		81.3	105.1
Total assets		2,075.0	2,045.4
LIABILITIES			
Current liabilities			
Interest-bearing liabilities		11.9	8.8
Lease liabilities		14.7	14.7
Trade and other payables		233.3	224.6
Provisions		15.6	13.8
Tax payable		149.6	48.0
Derivative financial instruments	5	2.4	4.4
Total current liabilities		427.5	314.3

	Notes	Audited 31 March 2021 NZ\$M	Unaudited 30 September 2021 NZ\$M
LIABILITIES			
Non-current liabilities			
Interest-bearing liabilities		62.8	63.5
Lease liabilities		29.0	27.5
Provisions		10.5	22.7
Other payables		22.8	22.0
Derivative financial instruments	5	1.5	4.6
Total liabilities		554.1	454.6
EQUITY			
Share capital		249.1	255.5
Retained earnings		1,029.2	1,124.2
Reserves		242.6	211.1
Total equity		1,520.9	1,590.8
Total liabilities and equity		2,075.0	2,045.4

The accompanying notes form an integral part of the financial statements.

On behalf of the Board
24 November 2021

Scott St John
Board Chair

Lewis Gradon
Managing Director and Chief Executive Officer

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 September 2021

	Unaudited 2020 NZ\$M	Unaudited 2021 NZ\$M
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	884.0	883.1
Interest received	0.8	1.0
Payments to suppliers and employees	(583.3)	(565.9)
Tax paid	(80.7)	(188.0)
Interest paid	(1.9)	(1.9)
Lease interest paid	(0.8)	(0.8)
Net cash flows from operating activities	218.1	127.5
CASH FLOWS FROM INVESTING ACTIVITIES		
Net short-term investments	12.6	95.1
Purchases of property, plant and equipment	(78.4)	(64.8)
Purchases of intangible assets	(16.1)	(16.5)
Net cash flows from investing activities	(81.9)	13.8
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of share capital under employee share plans	1.5	1.5
Lease liability payments	(5.3)	(6.6)
Dividends paid	(89.1)	(126.8)
Net cash flows from financing activities	(92.9)	(131.9)
Net increase in cash	43.3	9.4
Opening cash	36.4	85.4
Effect of foreign exchange rates	(0.5)	(0.4)
Closing cash	79.2	94.4
RECONCILIATION OF CLOSING CASH		
Cash and cash equivalents	93.2	103.2
Bank overdrafts	(14.0)	(8.8)
Closing cash	79.2	94.4

	Unaudited 2020 NZ\$M	Unaudited 2021 NZ\$M
CASH FLOW RECONCILIATION		
Profit after tax	225.5	221.8
Add (deduct) non-cash items:		
Depreciation – right-of-use assets	5.0	6.7
Depreciation and amortisation – other assets	32.0	39.3
Share based payments	3.7	3.7
Movement in provisions	7.8	10.4
Movement in deferred tax assets / liabilities	(21.4)	(11.7)
Movement in net tax payables	32.0	(107.2)
Foreign currency translation	(7.4)	1.0
Other non-cash items	3.8	(0.3)
	55.5	(58.1)
Net working capital movements:		
Trade and other receivables	(14.1)	(8.4)
Inventories	(87.1)	(21.3)
Trade and other payables	38.3	(6.5)
	(62.9)	(36.2)
Net cash flows from operating activities	218.1	127.5

The accompanying notes form an integral part of the financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 September 2021

1. GENERAL INFORMATION

Reporting entity

Fisher & Paykel Healthcare Corporation Limited (the “Company” or “Parent”) together with its subsidiaries (the “Group”) is a leading designer, manufacturer and marketer of medical device products and systems for use in both hospital and homecare settings. Products are sold in over 120 countries worldwide. The Company is a limited liability company incorporated and domiciled in New Zealand.

Statement of compliance

The Company is registered under the Companies Act 1993 and is an FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The Company is also listed on the New Zealand Stock Exchange (NZX) and the Australian Securities Exchange (ASX).

Basis of preparation

These consolidated financial statements for the six months ended 30 September 2021 have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (NZ GAAP). They comply with New Zealand Equivalent to International Accounting Standard 34: Interim Financial Reporting (NZ IAS 34) and International Accounting Standard 34: Interim Financial Reporting (IAS 34). The Company and Group are designated as profit-oriented entities for financial reporting purposes.

These consolidated financial statements do not include all of the notes normally included in an annual financial report. Accordingly, this report should be read in conjunction with the audited consolidated financial statements for the year ended 31 March 2021.

Presentation currency

These consolidated financial statements are presented in New Zealand dollars (NZD) to the nearest hundred thousand dollars unless otherwise stated.

Accounting policies

All accounting policies have been applied on a basis consistent with those used and described in the audited consolidated financial statements for the year ended 31 March 2021.

2. SIGNIFICANT TRANSACTIONS AND EVENTS FOR THE CURRENT PERIOD

The following significant transactions and events affected the financial performance and financial position of the Group for the six month period ended 30 September 2021:

COVID-19

In March 2020, the World Health Organisation declared the outbreak of COVID-19 as a pandemic. Since the outbreak of COVID-19, the Company's focus has been on manufacturing and supplying products that are directly involved in treating patients with COVID-19.

Management have assessed the impact of COVID-19 on all aspects of the balance sheet. Specifically, the carrying value of receivables, inventory and warranty exposure were considered, with provisioning reflecting management's best estimate of the impact based on information available at the time of preparing these financial statements. There has been no material impact on the balance sheet.

Share capital

During the six months ended 30 September 2021, the Group issued 689,563 shares under employee equity plans.

Funding and short-term investments

The Company had total available committed debt funding of NZ\$248 million as at 30 September 2021, of which approximately NZ\$185 million was undrawn. As at 30 September 2021, the weighted average maturity of borrowing facilities was 2.6 years.

As at 30 September 2021, the Group has invested available cash on hand of \$185 million in short-term investments. These investments have maturities between 100 and 277 days with banking institutions that have a long term credit rating of Standard & Poors' A- and above and are invested at average interest rates of 1.1%.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

3. OPERATING REVENUE AND SEGMENTAL INFORMATION

	Unaudited 2020 NZ\$M	Unaudited 2021 NZ\$M
For the six months ended 30 September		
Sales revenue	910.6	879.6
Foreign exchange (loss)/gain on hedged sales	(0.4)	20.4
Total operating revenue	910.2	900.0
Revenue by product group		
Hospital products	681.0	670.2
Homecare products	226.2	226.9
	907.2	897.1
Distributed and other products	3.0	2.9
Total operating revenue	910.2	900.0
Revenue after hedging by geographical location of customer:		
North America	373.9	329.8
Europe	269.9	232.0
Asia Pacific	184.4	267.2
Other	82.0	71.0
Total operating revenue	910.2	900.0

4. OPERATING EXPENSES

	Unaudited 2020 NZ\$M	Unaudited 2021 NZ\$M
For the six months ended 30 September		
Profit before tax includes the following expenses:		
Depreciation - right-of-use assets	5.0	6.7
Depreciation and amortisation - other assets	32.0	39.3
Employee benefits expense	287.8	296.3

5. DERIVATIVE FINANCIAL INSTRUMENTS

Financial instruments are either carried at amortised cost, less any provision for impairment, or fair value. The carrying value of all financial assets and liabilities approximates fair value.

There have been no changes to the Group's hedging policy during the period. The Group enters into foreign currency option contracts or forward foreign currency contracts within policy parameters to manage the net risk associated with anticipated sales or costs. The Group generally applies hedge accounting to all derivative financial instruments.

All derivative financial instruments continue to be re-measured to their fair value. Derivative financial instruments continue to be classified as being within Level 2 of the fair value hierarchy and there were no changes in valuation techniques during the period.

Contractual amounts of derivative financial instruments were as follows:

	Audited 31 March 2021 NZ\$M	Unaudited 30 September 2021 NZ\$M
Foreign currency forward contracts and options		
Sale commitments forward exchange contracts	1,743.5	1,769.8
Purchase commitments forward exchange contracts	83.2	82.3
Foreign currency borrowing forward exchange contracts	36.1	36.2
NZD call option contracts purchased	-	24.8
Collar option contracts - NZD call options purchased (i)	31.9	31.9
Collar option contracts - NZD put options sold (i)	34.0	34.0
Interest rate derivatives		
Interest rate swaps	29.0	29.3
Interest rate options	10.7	10.9

(i) Foreign currency contractual amounts of put and call options are equal.

Undiscounted foreign currency contractual amounts for outstanding hedges were as follows:

	Audited 31 March 2021 M	Unaudited 30 September 2021 M
Sale Commitments		
United States dollars	US\$627.5	US\$648.5
European Union euros	€280.7	€286.8
Japanese yen	¥8,485.0	¥9,467.5
Purchase Commitments		
Mexican pesos	MX\$1,314.5	MX\$1,309.0

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

6. COMMITMENTS

	Audited 31 March 2021 NZ\$M	Unaudited 30 September 2021 NZ\$M
Capital expenditure commitments contracted for but not recognised as at the reporting date:		
Within one year	45.9	52.8
Between one and two years	9.2	–
Between two and five years	–	7.1
	55.1	59.9

7. CONTINGENT LIABILITIES

Periodically the Group is party to litigation including product liability and patent claims.

The Directors are unaware of the existence of any claim or contingencies that would have a material impact on the operations of the Group.

8. RELATED PARTY TRANSACTIONS

During the period the Group has not entered into any material contracts involving related parties or Directors' interests. No amounts owed by related parties have been written off or forgiven during the period. Apart from Directors' fees, key executive remuneration and dividends paid by the Group to its Directors as shareholders of the company, there have been no related party transactions.

9. DIVIDENDS

On 26 May 2021 the Directors approved the payment of a fully imputed 2021 final dividend of \$126.8 million (22.0 cents per share) which was paid on 7 July 2021. A supplementary dividend of 3.8824 cents per share was also paid to eligible non-resident shareholders.

Subsequent event – dividend declared

On 24 November 2021 the Directors approved the payment of a fully imputed 2022 interim dividend of \$98.1 million (17 cents per share) to be paid on 15 December 2021. A supplementary dividend of 3 cents per share was also approved for eligible non-resident shareholders.

10. SUBSEQUENT EVENTS

There are no other subsequent events other than the dividend as set out in Note 9.



INDEPENDENT AUDITOR'S REVIEW REPORT

To the shareholders of Fisher & Paykel Healthcare Corporation Limited

REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS

OUR CONCLUSION

We have reviewed the consolidated financial statements of Fisher & Paykel Healthcare Corporation Limited (the Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 30 September 2021, and the consolidated income statement, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six months period ended on that date, and other explanatory information.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 30 September 2021, and its financial performance and cash flows for the six months period then ended on that date, in accordance with International Accounting Standard 34 *Interim Financial Reporting* (IAS 34) and New Zealand Equivalent to International Accounting Standard 34 *Interim Financial Reporting* (NZ IAS 34).

BASIS FOR CONCLUSION

We conducted our review in accordance with the New Zealand Standard on Review Engagements 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* (NZ SRE 2410 (Revised)). Our responsibility is further described in the *Auditor's responsibility for the review of the financial statements* section of our report.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. In addition to our role as auditor, our firm carries out other services for the Group in the areas of executive remuneration benchmarking and providing market survey data, regulatory tax compliance procedures in Mexico, and other assurance services in relation to constant currency disclosures. The provision of these other services has not impaired our independence.

DIRECTORS' RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Directors of the Company are responsible on behalf of the Company for the preparation and fair presentation of these consolidated financial statements in accordance with IAS 34 and NZ IAS 34 and for such internal control as the Directors determine is necessary to enable the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

AUDITOR'S RESPONSIBILITY FOR THE REVIEW OF THE FINANCIAL STATEMENTS

Our responsibility is to express a conclusion on the consolidated financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the consolidated financial statements, taken as a whole, are not prepared in all material respects, in accordance with IAS 34 and NZ IAS 34. A review of consolidated financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.


The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing and International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated financial statements.

WHO WE REPORT TO

This report is made solely to the Company's Shareholders, as a body. Our review work has been undertaken so that we might state to the Company's Shareholders those matters which we are required to state to them in our review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Shareholders, as a body, for our review procedures, for this report, or for the conclusion we have formed.

The engagement partner on the review resulting in this independent auditor's review report is Keren Blakey.

For and on behalf of:

The logo for PricewaterhouseCoopers, featuring the company name in a stylized, cursive script.

Chartered Accountants

24 November 2021

Auckland



Directory

DIRECTORS

Scott St John	Board Chair, Non-Executive, Independent
Lewis Gradon	Managing Director and Chief Executive Officer
Michael Daniell	Non-Executive
Pip Greenwood	Non-Executive, Independent
Geraldine McBride	Non-Executive, Independent
Dr Lisa McIntyre	Non-Executive, Independent
Neville Mitchell	Non-Executive, Independent
Donal O'Dwyer	Non-Executive, Independent

EXECUTIVE MANAGEMENT TEAM

Lewis Gradon	Managing Director and Chief Executive Officer
Lyndal York	Chief Financial Officer
Paul Shearer	Senior Vice President – Sales & Marketing
Andrew Somervell	Vice President – Products & Technology
Winston Fong	Vice President – Surgical Technologies
Brian Schultz	Vice President – Quality & Regulatory Affairs
Nicholas Fourie	Vice President – Information & Communication Technology
Jonti Rhodes	General Manager – Supply Chain, Facilities & Sustainability
Marcus Driller	Vice President – Corporate
Nicola Talbot	Vice President – Human Resources

REGISTERED OFFICES

New Zealand:

Physical address:	15 Maurice Paykel Place, East Tamaki, Auckland 2013, New Zealand
Telephone:	+64 9 574 0100
Postal address:	PO Box 14348, Panmure, Auckland 1741, New Zealand
Website:	www.fphcare.com
Email:	investor@fphcare.co.nz

Australia:

Physical address:	19-31 King St, Nunawading, Melbourne, Victoria 3131, Australia
Telephone:	+61 3 9871 4900
Postal address:	PO Box 159, Mitcham Victoria 3132, Australia

STOCK EXCHANGES

The Company's ordinary shares are listed on the NZX Main Board and the ASX.

SHARE REGISTRAR

In New Zealand:


Link Market Services Limited

Physical address:	Level 30, PwC Commercial Bay, 15 Customs Street West, Auckland 1010, New Zealand
Postal address:	PO Box 91976, Auckland 1142, New Zealand
Facsimile:	+64 9 375 5990
Investor enquiries:	+64 9 375 5998
Website:	www.linkmarketservices.co.nz
Email:	enquiries@linkmarketservices.co.nz

In Australia:

Link Market Services Limited

Physical address:	Level 12, 680 George Street, Sydney, NSW 2000, Australia
Postal address:	Locked Bag A14, Sydney South, NSW 1235, Australia
Facsimile:	+61 2 9287 0303
Investor enquiries:	+61 2 8280 7111
Internet address:	www.linkmarketservices.com.au
Email:	registrars@linkmarketservices.com.au



— Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.

Forward, together.

Important notice

Disclaimer

The information in this presentation is for general purposes only and should be read in conjunction with Fisher & Paykel Healthcare Corporation Limited's (FPH) Interim Report 2022 and accompanying market releases. Nothing in this presentation should be construed as an invitation for subscription, purchase or recommendation of securities in FPH.

This presentation includes forward-looking statements about the financial condition, operations and performance of FPH and its subsidiaries. These statements are based on current expectations and assumptions regarding FPH's business and performance, the economy and other circumstances. As with any projection or forecast, the forward-looking statements in this presentation are inherently uncertain and susceptible to changes in circumstances. FPH's actual results may differ materially from those expressed or implied by those forward-looking statements.

Constant currency information included within this presentation is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A reconciliation between reported results and constant currency results is available in the company's Interim Report 2022. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half year business highlights

CONTRIBUTED to the fight against COVID-19 by providing convenient access to vaccinations for our employees.

LAUNCHED F&P Visairo™ mask for noninvasive ventilation and F&P Evora™ Full mask for obstructive sleep apnea.

APPOINTED Dr Lisa McIntyre to the Board of directors.

COMMENCED construction on our third manufacturing facility in Mexico and started earthworks on our fifth facility in New Zealand.

INITIATED search for property for a second R&D and manufacturing campus in New Zealand.

CONTINUED to expand our global reach by placing sales representatives into additional countries.


Key half year financial results

H1 FY22 (6 months to 30 September 2021)

	% of Revenue	NZ\$M	ΔPCP^	ΔCC*
Operating revenue	100%	900.0	-1%	2%
Hospital operating revenue	74%	670.2	-2%	1%
Homecare operating revenue	25%	226.9	0%	3%
Gross margin / Gross profit	63%	567.7	135bps	53bps
SG&A	21%	(189.6)	1%	5%
R&D	8%	(75.7)	17%	17%
Total operating expenses	29%	(265.3)	5%	8%
Operating profit	34%	302.4	-2%	-2%
Profit after tax	25%	221.8	-2%	-1%

Hospital product group

H1 FY22 HOSPITAL REVENUE COMPOSITION



■ Hardware ■ Consumables

H1 FY21 Hospital revenue composition
Hardware: 37% Consumables: 63%

HARDWARE



F&P 950 System



F&P 850 System



F&P AIRVO2



F&P HumiGard

CONSUMABLES



Invasive ventilation



Noninvasive ventilation



Optiflow™ nasal high flow



Surgical



Hospital product group

H1 FY22

74% OF OPERATING
REVENUE

HOSPITAL OPERATING REVENUE
(H1 FY22 \$670.2M)

NZ\$ **↓ -2%**

CONSTANT
CURRENCY **↑ 1%**

NEW APPLICATIONS*
CONSUMABLES REVENUE

NZ\$ **↑ 20%**


CONSTANT
CURRENCY **↑ 24%**



- Strong customer demand for our Optiflow and Airvo systems, driven by the growing body of clinical evidence and COVID-19
- New applications consumables* made up 72% of H1 FY22 Hospital consumables revenue, 63% in H1 FY21
- H1 FY22 Hospital hardware declined 10% in constant currency

Homecare product group

H1 FY22 HOMECARE REVENUE COMPOSITION



■ Hardware ■ Consumables

HARDWARE



F&P SleepStyle



F&P myAIRVO 2



F&P 810System

CONSUMABLES



CPAP Therapy/OSA



Home Respiratory Support



F&P Evora Full



F&P Evora



F&P Brevida



**Fisher & Paykel
HEALTHCARE**

H1 FY21 Homecare revenue composition
Hardware: 17% Consumables: 83%

Homecare product group

H1 FY22

25% OF OPERATING
REVENUE

HEMOCARE OPERATING REVENUE
(H1 FY22 \$226.9M)

NZ\$

0%

CONSTANT
CURRENCY



3%

MASKS REVENUE

NZ\$



-1%

CONSTANT
CURRENCY




3%



F&P Evora Full

- Introduced F&P Evora Full, a compact full-face mask, in Australia and New Zealand
- OSA mask revenue impacted by reduced new patient diagnosis, due to the impact of COVID-19 and the limited supply of treatment hardware


Gross Margin



..... Long Term Gross Margin target

- Gross margin for the half year:
 - increased by 135 bps to 63.1%
 - increased by 53 bps in constant currency
 - freight remained elevated but lower than prior half year
- Increased freight costs adversely impacted constant currency gross margin by ~190bps compared to pre-COVID-19 levels

Operating Margin



Operating expenses

- \$265.3M, +5% (+8% CC)
- Operating margin decreased by 37 bps (-121 bps CC) to 33.6% with continued investment in operating expenses to support hardware sales

Research & Development expenses

- \$75.7M, +17% (+17% CC)
- Reflecting underlying growth and timing of R&D projects
- Estimate ~65% of R&D spend eligible for tax credit

Selling, General & Administrative expenses


- \$189.6M, +1% (+5% CC)

Cash Flow and Balance Sheet

	H1 FY21 NZ\$M	H1 FY22 NZ\$M
Operating cash flow	218.1	127.5
Capital expenditure (including purchases of intangible assets)	94.5	81.3
Lease liability payments	5.3	6.6
Free cash flow	118.3	39.6
	FY21 NZ\$M	H1 FY22 NZ\$M
Net cash / (debt) (including short-term investments)	302.9	216.1
Total assets	2,075.0	2,045.4
Total equity	1,520.9	1,590.8
Gearing (net debt / net debt + equity)*	-27.2%	-16.6%

Dividend

- Increased interim dividend by 6%
 - 17.00 cps + 6.6111 cps imputation credit for NZ residents (gross dividend of NZ 23.6111 cps)
 - Fully imputed
 - 3.0000 cps non-resident supplementary dividend



Foreign exchange effects

- 49% of operating revenue in US\$ (FY21: 52%) and 17% in € (FY21: 19%).

	Year to 31 March				
Hedging position for our main exposures	FY22	FY23	FY24	FY25	FY26-27
USD % cover of estimated exposure	95%	70%	50%	30%	-
USD average rate of cover	0.675	0.665	0.656	0.624	-
EUR % cover of estimated exposure	95%	70%	45%	35%	5%
EUR average rate of cover	0.554	0.537	0.526	0.508	0.481


Hedging cover percentages have been rounded to the nearest 5%

	H1 FY21 NZ\$M	H1 FY22 NZ\$M
Reconciliation of Constant Currency to Actual Income Statements		
Profit after tax (constant currency)	200.9	198.8
Spot exchange rate effect	29.2	5.4
Foreign exchange hedging result	(1.0)	15.2
Balance sheet revaluation	(3.6)	2.4
Profit after tax (as reported)	225.5	221.8

Revenue and expenses by currency


H1 FY22 (for the 6 months ended 30 September 2021)

REVENUE BY CURRENCY




■ NZD ■ USD ■ EUR ■ MXN ■ Other

COST OF SALES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

OPERATING EXPENSES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

H2 FY22 Observations

No quantitative guidance provided for the remainder of the 2022 financial year given the continuing uncertainties associated with COVID-19.

H2 FY22 Observations*

- **Hospital Consumables:** H2 FY21 peak COVID-19 hospitalisations in North America / Europe. In the absence of further comparable hospitalisation surges around the world, expect consumables revenue for H2 FY22 to be lower than H2 FY21. Continuing endemic COVID-19 hospitalisations, surgical activity approaching normality and the ongoing adoption of nasal high flow for applications other than COVID-19 would result in consumables revenue increasing sequentially from H1 FY22.
- **Hospital hardware:** do not expect Hospital hardware revenue to continue at an elevated level for H2 FY22.
- **Homecare:** continue to expect new OSA patient diagnoses to be at or above FY21 rates for H2 FY22.

*None of the observations listed is a prediction, forecast or guide for H2 FY22. Please refer to the full list of observations available in the company's news release dated 25 November 2021.

「Overview」



Fisher & Paykel Healthcare at a glance

Global leader in respiratory humidification devices

- Medical device manufacturer with leading positions in respiratory care and obstructive sleep apnea
- >50 years' experience in changing clinical practice to solutions that provide better clinical outcomes and improve effectiveness of care
- Estimated NZ\$20+ billion and growing market opportunity driven by demographics
- Significant organic long-term growth opportunities in respiratory care, OSA, COPD and surgery
- Large proportion (71%) of revenue from recurring items, consumables and accessories
- High level of innovation and investment in R&D with strong product pipeline
- High barriers to entry

Global presence

Our people
are located in
51 countries



3,793

in New Zealand

2,544

in North America,
including Mexico

371

in Europe

449

in the rest
of the world

Strong financial performance

- Continued target, and history of, doubling our revenue (in constant currency terms) every 5 to 6 years
- Targeting gross margin of 65% and operating margin of 30%
- Growth company with a strong history of increasing dividend payments

~NZ\$20+ billion and growing market opportunity

Total addressable market estimates

HOSPITAL

~90+ million patients

Invasive
Ventilation



Non-invasive
Ventilation



Hospital
Respiratory Support



Surgical
Humidification



NEW APPLICATIONS

Applications outside of invasive ventilation

HEMOCARE

~100+ million patients


Home Respiratory
Support



Obstructive Sleep
Apnea



Our aspiration




OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.

Markets and products



- Hospital
 - Heated humidification
 - Respiratory care
 - Neonatal care
 - Surgery
- Homecare
 - Masks
 - Flow generators
 - Data management tools
 - Respiratory care in the home

Recurring items, consumables and accessories approximately 71% of operating revenue (H1 FY21: 68%)




Impact of changing demographics


- Population age and weight both increasing
 - US population 65 years+ to grow ~80% over next 20 years¹
 - US males 60 - 74 years, average weight increased 0.4 kg/year since 1960²
- 60% of US healthcare cost is after age 65 years³
- Developing markets increasing healthcare spending
 - Total health spending is increasing more rapidly in low and middle income countries (close to 6% on average) than in high income countries (4%)⁴



Hospital cost breakdown



Lower care intensity = lower cost




「 Hospital 」



Respiratory humidification



- Normal airway humidification is bypassed or compromised during ventilation or oxygen therapy
- Mucociliary transport system operates less effectively
- Need to deliver gas at physiologically normal levels
 - 37°C body core temperature
 - 44mg/L 100% saturated



Optiflow - displacing conventional oxygen therapy

CONVENTIONAL OXYGEN THERAPY

NON-INVASIVE VENTILATION



Patient groups who may benefit from Optiflow

ADULTS:

- Acute respiratory failure
- Asthma
- Atelectasis
- Bronchiectasis
- Bronchitis
- Burns
- COPD
- Chest trauma
- Emphysema
- Palliative Care
- Pneumonia
- Pulmonary embolism
- Respiratory compromise
- Viral pneumonia
- Carbon monoxide poisoning

PAEDIATRICS/NEONATES:

- Infant respiratory distress
- Bronchiolitis



Clinical outcomes of Optiflow nasal high flow therapy

Optiflow NHF therapy is associated with:

ADULTS:

- REDUCED intubation⁶
- REDUCED re-intubation^{7, 8, 9}
- REDUCED bilevel ventilation⁸
- REDUCED nursing workload⁸
- INCREASED ventilator free days⁶
- IMPROVED comfort & patient tolerance⁷
- IMPROVED compliance⁷
- REDUCED COPD exacerbations¹⁰

PAEDIATRICS:


- REDUCED intubation¹¹
- REDUCED length of stay¹²
- REDUCED respiratory distress¹³

NEONATES:

- NON-INFERIORITY with nasal CPAP¹⁴
- REDUCED nasal trauma^{15, 16}
- REDUCED respiratory distress¹⁷

Optiflow NHF - a growing body of clinical evidence

NASAL HIGH FLOW CLINICAL PAPERS PUBLISHED ANNUALLY



- The publication of 638 clinical papers on NHF continues to signify a high level of clinical interest in the therapy

International Clinical Practice Guidelines



Management of Adult Patients With Oxygen in the Acute Care Setting

Summary: The findings are consistent with a published systematic review and meta-analysis and subsequent clinical practice guidelines by Rochwerg et al. These clinical practice guidelines gave a

1. strong recommendation for HFNC over conventional oxygen therapy (COT) for hypoxemic respiratory failure
2. a conditional recommendation for use immediately postextubation, and postoperatively in cardiac and/or thoracic surgery patients.
3. Further data are required to demonstrate mortality benefits or confirm benefits in ICU or hospitalLOS with HFNC compared to COT in any patient population.

Napolitano et al (2021) AACRC Clinical Practice Guideline: Management of Pediatric Patients With Oxygen in the Acute Care Setting. Respiratory Care (<http://rc.rcjournal.com/content/early/2021/11/02/respcare.09294/tab-pdf>)



ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure

Result: The Task Force developed 8 conditional recommendations, suggesting using:

1. HFNC over COT in hypoxemic ARF,
2. HFNC over NIV in hypoxemic ARF,
3. HFNC over COT during breaks from NIV,
4. either HFNC or COT in post-operative patients at low risk of pulmonary complications,
5. either HFNC or NIV in post-operative patients at high risk of pulmonary complications,
6. HFNC over COT in non-surgical patients at low risk of extubation failure,
7. NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV,
8. trialling NIV prior to use of HFNC in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic ARF.

Oczkowski S, Ergon Büm, Bos L, et al. ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J 2021; in press (<https://doi.org/10.1183/13993003.01574-2021>).



The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline


Result: The guideline panel made four recommendations:

1. strong recommendation for HFNC in hypoxemic respiratory failure compared to COT (moderate certainty),
2. conditional recommendation for HFNC following extubation (moderate certainty),
3. no recommendation regarding HFNC in the peri-intubation period (moderate certainty),
4. conditional recommendation for postoperative HFNC in high risk and/or obese patients following cardiac or thoracic surgery (moderate certainty).

Rochwerg et al (2020) The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Med




Clinical practice guideline: NHF evidence from the ED

	Flow rate up to (L/min)		Reduced escalation	Reduced respiratory rate	Improve oxygenation	Reduced PaCO ₂	Reduced dyspnea	Improves comfort
Bell ²⁹ 2015	 50 vs COT		●	●			●	●
Cortegiani ³⁰ 2020	 60 vs NIV					●		
Doshi ³¹ 2018	 35 vs NIV		●			●		
Geng ³² 2020	 60 vs COT			●	●			
Jones ³³ 2016	 40 vs COT					●		
Ko ³⁴ 2020	 60 vs COT			●	●	●		
Makdee ³⁵ 2017	 60 vs COT			●	○			
Papachatzakis ³⁶ 2020	 50 vs NIV			○		○		
Raeisi ³⁷ 2019	 35 vs COT			○	○		●	
Rittayamai ³⁸ 2015	 60 vs COT				●		●	●
Ruangsomboon ³⁹ 2019	 60 vs COT			●	●		●	

● Significant difference
○ Demonstrates trend towards outcome

Strong growth in hospital new applications



- New applications consumables currently make up 72% of Hospital consumables revenue, from 63% in H1 FY21

「Homecare」



Obstructive Sleep Apnea

- Temporary closure of airway during sleep
- Can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack
- Estimate >100 million people affected in developed countries
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
 - Key issue with CPAP is compliance
 - Humidification provides significant acceptance and compliance improvements



Mask matters most


- Masks are key to compliance
- Unique, patented designs
- Released F&P Evora compact full-face mask in Australia and New Zealand and will be launched in other countries upon receiving clearances.



F&P EVORA NASAL™
F&P Evora



F&P EVORA FULL-FACE™
F&P Evora Full



F&P BREVIDA™
F&P Brevida

Home respiratory support

- Chronic obstructive pulmonary disease (COPD) is a lung disease which is commonly associated with smoking
- Emphysema and chronic bronchitis are both forms of COPD
- Chronic respiratory disease, primarily COPD, is the third leading cause of death in the world¹⁷
- 6% of US adults have been diagnosed with COPD¹⁸ (~15 million people)
- 4-10% COPD prevalence worldwide¹⁹ (~400 million people)
- Emerging evidence for COPD patients using NHF at home, reduced exacerbation rates¹⁰, reduced hypercapnia^{27,28}, and improved Quality of life^{10,27}.




High level of innovation and investment in R&D

- R&D represents 8% of operating revenue*: NZ\$75.7M
- Product pipeline includes:
 - Humidifier controllers
 - Masks
 - Respiratory consumables
 - Flow generators
 - Compliance monitoring solutions
- 411 US patents, 491 US pending, 1,699 Rest of world patents, 1,141 Rest of world pending[†]



Growing patent portfolio



Average remaining life of FPH patent portfolio (all countries): 11.7 years*

Manufacturing and operations

New Zealand

- Four buildings: 110,000 m² / 1,180,000 ft²
- Co-location of R&D and manufacturing
- Commenced earthworks on building 5
- Initiated search for second R&D and manufacturing campus in New Zealand

Tijuana, Mexico

- Two buildings: 41,000 m² / 450,000 ft²
- Commenced construction of a 22,000 m² / 240,000 ft² third manufacturing facility in Mexico

Future manufacturing

- Planning two additional facilities outside of New Zealand over the next five years



Mexico 3 – Construction progressing well on the third manufacturing facility in Tijuana, Mexico.

Environmental, Social & Governance

ESG Summary

People

Supporting our people: Through an internal campaign called unite in the fight. We reminded our people of the vital role their work was playing in the treatment of COVID-19 patients.

Community

Fisher & Paykel Healthcare Foundation: The purposes of this charitable organisation include supporting and funding health research, improving access to healthcare, environmental protection initiatives and promoting STEM.

Environment

CDP Scores	FY19	FY20	FY21
Climates	B	B	A-
Supplier Engagement	-	B-	A-
Water	-	C	B
Forests	-	-	C

Disclosure:
During FY21
we began
disclosing
CDP forests.



\$20 million
TO ESTABLISH THE NEW
FISHER & PAYKEL HEALTHCARE
FOUNDATION



Sustainability disclosures and indices

We participate annually in a suite of well-respected sustainability disclosure programmes and have been included this year in the Dow Jones Sustainability Index and the FTSE4Good index.

Member of
**Dow Jones
Sustainability Indices**


Powered by the S&P Global CSA



FTSE4Good

Strong global presence


- **Direct/offices**
 - Hospitals, home care dealers
 - Sales/support offices in North America, Europe, Asia, South America, Middle East and Australasia, 18 distribution centres
 - ~1,100 employees in 51 countries
 - Ongoing international expansion
- **Distributors**
 - +180 distributors worldwide
- **Original Equipment Manufacturers**
 - Supply most leading ventilator manufacturers
- **Sell in more than 120 countries**




Ownership structure and listings

- Listed on NZX and ASX (NZX.FPH, ASX.FPH)

SHAREHOLDING STRUCTURE AS AT
30 SEPTEMBER 2021



GEOGRAPHICAL OWNERSHIP AS AT
30 SEPTEMBER 2021



Consistent growth strategy

SUSTAINABLE, PROFITABLE GROWTH

We aim to grow our business in a way that is sustainable over the long term.



References

References

1. Clinical guidelines for use of NHF on Covid-19 patients, including those issued by the HHS, WHO, SCCM, ACEP, NIH and the CDC.
2. Grayson K, Vincent, Victoria A, Velkoff. The Next Four Decades. The Older Population in the United States: 2010 to 2050. US Census Bureau, 2010.
3. Cynthia L Ogden, Cheryl D Fryar et al. Mean Body Weight, Height, and Body Mass Index (BMI) 1960-2002. US Centers for Disease Control and Prevention, 2004.
4. Berhanu Alemayehu, Kenneth E Warner. The Lifetime Distribution of Health Care Costs. Health Serv Res. 2004 June; 39(3): 627-642
5. KeX, Agnes S et al. Public Spending on Health: A Closer Look at Global Trends. World Health Organisation 2018.
6. Frat JP, Thille AW, Mercat A et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015;372(23):2185-96
7. Maggiore SM, Idone FA, Vaschetto R et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med*. 2014;190(3):282-8
8. Stéphan F, Barrucand B, Petit P et al. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. *JAMA*. 2015;313(23):2331-9
9. Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. *JAMA*. 2016;315(13):1354-1361. doi:10.1001/jama.2016.2711
10. Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. *Int J Chron Obstruct Pulmon Dis* 2018;16;13:1195-1205
11. Wing R, James C, Maranda LS et al. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. *Pediatr Emerg Care*. 2012;28(11):1117-23
12. McKiernan C, Chua LC, Visintainer PF et al. High flow nasal cannulae therapy in infants with bronchiolitis. *J Pediatr*. 2010;156(4):634-8
13. Milési C, Baleine J, Matecki S et al. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. *Intensive Care Med*. 2013 Jun;39(6):1088-94
14. Manley BJ, Owen LS, Doyle LW et al. High-flow nasal cannulae in very preterm infants after extubation. *N Engl J Med*. 2013;369(15):1425-33
15. Yoder BA, Stoddard RA, Li M, King J et al. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. *Pediatrics*. 2013;131(5):e1482-90
16. Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. *J Pediatr*. 2013;162(5):949-54
17. Saslow JG, Aghai ZH, Nakhla TA et al. Work of breathing using high-flow nasal cannula in preterm infants. *J Perinatol*. 2006;26(8):476-80
18. World Health Organisation (2018) The top 10 causes of death, Available at: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (Accessed: 24 May 2018)
19. Nicole M Kosacz, Antonello Punturieri et al. Chronic Obstructive Pulmonary Disease Among Adults -United States 2011. US Centers for Disease Control and Prevention, 2012.
20. R J Halbert, Sharon Isonaka, Dorothy George, Ahmar Iqbal. Interpreting COPD Prevalence Estimates. *Chest*. 2003; 123:5 1684 - 1692.
21. Rochweg B, Granton D, Wang DX et al (2019) High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. *Intensive Care Med* 45(5):563-572.
22. Chaudhuri D, Granton D, Wang DX, Burns KEA, Helviz Y, Einav S, Trivedi V, Mauri T, Ricard JD, Mancebo J, Frat JP, Jog S, Hernandez G, Maggiore SM, Mbuagbaw L, Hodgson CL, Jaber S, Goligher EC, Brochard L, Rochweg B. High-Flow Nasal Cannula in the Immediate Postoperative Period: A Systematic Review and Meta-analysis. *Chest*. 2020 Nov;158(5):1934-1946. doi: 10.1016/j.chest.2020.06.038. Epub 2020 Jun 29. PMID: 32615190..
23. Chaudhuri D, Granton D, Wang DX et al (2020) Moderate certainty evidence suggests the use of high-flow nasal cannula does not decrease hypoxia when compared with conventional oxygen therapy in the peri-intubation period: results of a systematic review and meta-analysis. *Critical Care Med*.
24. Granton D, Chaudhuri D, Wang D, et al. High-Flow Nasal Cannula Compared With Conventional Oxygen Therapy or Noninvasive Ventilation Immediately Postextubation: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2020;48(11):e1129-e1136. doi:10.1097/CCM.0000000000004576.
25. Rochweg B, Einav S, Chaudhuri D, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. *Intensive Care Med*. 2020;46(12):2226-2237. doi:10.1007/s00134-020-06312-y.
26. Millar J, Lutton S, O'Connor P. The use of high-flow nasal oxygen therapy in the management of hypercarbic respiratory failure. *Ther Adv Respir Dis*. 2014;8(2):63-64. doi:10.1177/1753465814521890..
27. Pavlov I, Plamondon P, Delisle S. Nasal high-flow therapy for type II respiratory failure in COPD: a report of four cases. *Respir Med Case Rep*. 2017;20:87-88. doi:10.1016/j.rmcr.2016.12.006.
28. Rittayamai N, Phuangchoei P, Tscheikuna J, et al. Effects of high-flow nasal cannula and non-invasive ventilation on inspiratory effort in hypercapnic patients with chronic obstructive pulmonary disease: a preliminary study. *Ann Intensive Care*. 2019; 9(1):122doi:10.1186/s13613-019-0597-5.
29. Bell N, Hutchinson CL, Green TC, Rogan E, Bein KJ, Dinh MM. Randomised control trial of humidified high flow nasal cannulae versus standard oxygen in the emergency department. *Emerg Med Australas*. 2015;27(6):537-41.
30. Cortegiani A, Longhini F, Madotto F, Groff P, Scala R, Crimi C, et al. High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized trial. *Critical Care*. 2020;24(1):1-13.
31. Doshi P, Whittle JS, Bublewicz M, Kearney J, Ashe T, Graham R, et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. *Ann Emerg Med*. 2018;72(1):73-83.e5.
32. Geng W, Batu W, You S, Tong Z, He H. High-Flow Nasal Cannula: A Promising Oxygen Therapy for Patients with Severe Bronchial Asthma Complicated with Respiratory Failure. *Can Respir J*. 2020;2020:2301712.
33. Jones PG, Kamona S, Doran O, Sawtell F, Wilsher M. Randomized Controlled Trial of Humidified High-Flow Nasal Oxygen for Acute Respiratory Distress in the Emergency Department: The HOT-ER Study. *Respir Care*. 2016;61(3):291-9.
34. Ko DR, Beom J, Lee HS, You JS, Chung HS, Chung SP. Benefits of high-flow nasal cannula therapy for acute pulmonary edema in patients with heart failure in the emergency department: a prospective multi-center randomized controlled trial. *Journal of clinical medicine*. 2020;9(6):1937.
35. Makdee O, Monsomboon A, Surabenjawong U, Praphruetkit N, Chaisirin W, Chakorn T, et al. High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Emergency Department Patients With Cardiogenic Pulmonary Edema: A Randomized Controlled Trial. *Ann Emerg Med*. 2017;70(4):465-72.e2.
36. Papachatzakis Y, Nikolaidis PT, Kontogiannis S, Trakada G. High-Flow Oxygen through Nasal Cannula vs. Non-Invasive Ventilation in Hypercapnic Respiratory Failure: A Randomized Clinical Trial. *Int J Environ Res Public Health*. 2020 Aug;17(16):5994.
37. Raeisi S, Fakharian A, Ghorbani F, Jamaati HR, Mirenayat MS. Value and Safety of High Flow Oxygenation in the Treatment of Inpatient Asthma: A Randomized, Doubleblind, Pilot Study. *Iran*. 2019;18(6):615-23.
38. Rittayamai N, Tscheikuna J, Praphruetkit N, Kijpinyochai S. Use of High-Flow Nasal Cannula for Acute Dyspnea and Hypoxemia in the Emergency Department. *Respir Care*. 2015;60(10):1377-82.
39. Ruangsomboon O, Dorongthom T, Chakorn T, Monsomboon A, Praphruetkit N, Limsuwat C, et al. High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Relieving Dyspnea in Emergency Palliative Patients With Do-Not-Intubate Status: A Randomized Crossover Study. *Ann Emerg Med*. 2019;18:18.

25 November 2021

Results announcement

Results for announcement to the market		
Name of issuer	Fisher & Paykel Healthcare Corporation Limited	
Reporting Period	6 months to 30 September 2021	
Previous Reporting Period	6 months to 30 September 2020	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$900,000	-1%
Total Revenue	\$900,000	-1%
Net profit/(loss) from continuing operations	\$221,800	-2%
Total net profit/(loss)	\$221,800	-2%
Interim Dividend		
Amount per Quoted Equity Security	0.17000000 \$/share	
Imputed amount per Quoted Equity Security	0.06111111 \$/share	
Record Date	03 December 2021	
Dividend Payment Date	15 December 2021	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	2.42989359 \$/share	1.87047145 \$/share
A brief explanation of any of the figures above necessary to enable the figures to be understood	Not applicable	
Authority for this announcement		
Name of person authorised to make this announcement	Raelene Leonard	
Contact person for this announcement	Raelene Leonard	
Contact phone number	+64 9 574 0147	
Contact email address	companysecretary@fphcare.co.nz	
Date of release through MAP	25 November 2021	

Reviewed financial statements accompany this announcement.

25 November 2021
Distribution Notice

Section 1: Issuer information				
Name of issuer	Fisher & Paykel Healthcare Corporation Limited			
Financial product name/description	Interim Dividend			
NZX ticker code	FPH			
ISIN	NZFAPE0001S2			
Type of distribution	Full Year		Quarterly	
	Half Year	X	Special	
	DRP applies			
Record date	03 December 2021			
Ex-Date	02 December 2021			
Payment date	15 December 2021			
Total monies associated with the distribution	\$98,121,968 million based on shares on issue at 24 November 2021 for cash distribution			
Source of distribution	Retained earnings			
Currency	NZD			
Section 2: Distribution amounts per financial product				
Gross distribution	0.23611111 \$/share			
Gross taxable amount	0.23611111 \$/share			
Total cash distribution	0.17000000 \$/share			
Excluded amount	N/A			
Supplementary distribution amount	0.03000000 \$/share			
Section 3: Imputation credits and Resident Withholding Tax				
Is the distribution imputed	Fully imputed			
If fully or partially imputed, please state imputation rate as % applied	100%			
Imputation tax credits per financial product	0.06611111 \$/share			
Resident Withholding Tax per financial product	0.01180556 \$/share			
Section 4: Distribution re-investment plan (if applicable)				
Not applicable				
Section 5: Authority for this announcement				
Name of person authorised to make this announcement	Raelene Leonard			
Contact person for this announcement	Raelene Leonard			
Contact phone number	+64 9 574 0147			
Contact email address	companysecretary@fphcare.co.nz			
Date of release through MAP	25 November 2021			